Literature DB >> 9564848

Effect of interleukins on UGT2B15 and UGT2B17 steroid uridine diphosphate-glucuronosyltransferase expression and activity in the LNCaP cell line.

E Lévesque1, M Beaulieu, C Guillemette, D W Hum, A Bélanger.   

Abstract

Cytokines are known to modulate the level of both phase 1 and phase 2 drug-metabolizing enzymes in hepatocytes. Although the effects of cytokines on cytochrome P450 (CYP450) enzymes are well understood, there is limited knowledge on how cytokines may affect steroid UDP-glucuronosyltransferase (UGT) phase 2 enzyme activity and expression in different cell types, including hepatocytes and steroid target cells. LNCaP cells, which is a human prostate cancer cell line, is a good model to study the effect of cytokines in steroid target cells because it is known to express steroidogenic enzymes, including UGT2B15 and UGT2B17, which are widely expressed steroid UGT enzymes known to conjugate androgens. In this study, we examined the possible interaction among interleukin-1alpha (IL-1alpha), IL-4, IL-6, and steroid UGT enzymes (UGT2B15 and UGT2B17). Treatment of LNCaP cells with IL-1alpha led to a dose-dependent inhibition of dihydrotestosterone (DHT) glucuronidation. IL-1alpha decreased both UGT activity and LNCaP cell proliferation in the absence and presence of DHT (0.5 nM); a maximal inhibition of 70% was observed. IL-6 inhibited LNCaP cell proliferation as well as the DHT-induced proliferation of these cells. However, neither IL-4 nor IL-6 significantly affected the formation of DHT glucuronide. Ribonuclease protection and Western blot analyses demonstrated a specific reduction of UGT2B17 transcript and protein levels in IL-1alpha-treated LNCaP cells. The level of UGT2B15 was not affected by cytokine treatments, indicating a differential regulation between these two UGT enzymes. Transfection experiments performed with the UGT2B17 gene promoter region indicates that the regulation occurs at the transcription level via putative cis-acting elements. This study indicates that cell proliferation and UGT expression in steroid-responsive cancer cells are differentially regulated depending on the cytokines present in the cell microenvironment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9564848     DOI: 10.1210/endo.139.5.6001

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  4 in total

1.  Cloning and characterization of a simian UDP-glucuronosyltransferase enzyme UGT2B20, a novel C19 steroid-conjugating protein.

Authors:  O Barbier; A Bélanger; D W Hum
Journal:  Biochem J       Date:  1999-02-01       Impact factor: 3.857

2.  Chronic Chagas disease with low plasma concentrations of IL-6 does not have a major impact on nebivolol glucuronidation.

Authors:  Carolina Pinto Vieira; Daniel Valente Neves; Glauco Henrique Balthazar Nardotto; Evandro José Cesarino; Adriana Rocha; Ailton Marcelo Castilho Teno Zanardi; Vera Lucia Lanchote
Journal:  Eur J Clin Pharmacol       Date:  2020-01-25       Impact factor: 2.953

3.  Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway.

Authors:  Hannes Steiner; Sonia Godoy-Tundidor; Hermann Rogatsch; Andreas P Berger; Dietmar Fuchs; Barbara Comuzzi; Georg Bartsch; Alfred Hobisch; Zoran Culig
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

Review 4.  Classical and Non-Classical Roles for Pre-Receptor Control of DHT Metabolism in Prostate Cancer Progression.

Authors:  Ailin Zhang; Jiawei Zhang; Stephen Plymate; Elahe A Mostaghel
Journal:  Horm Cancer       Date:  2016-01-21       Impact factor: 3.869

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.